Abstract
The human sex hormone progesterone plays an essential and complex role in a number of physiological processes. Progesterone deficiency is associated with menstrual disorders and infertility as well as premature birth and abortion. For progesterone replacement therapy, the synthetic progestogen dydrogesterone is commonly used. In the body, this drug is metabolized to 20α-dihydrodydrogesterone (20α-DHD), which also shows extensive pharmacological effects and hence could act as a therapeutic agent itself. In this study, we describe an efficient biotechnological production procedure for 20α-DHD that employs the stereo- and regioselective reduction of dydrogesterone in a whole-cell biotransformation process based on recombinant fission yeast cells expressing the human enzyme AKR1C1 (20α-hydroxysteroid dehydrogenase, 20α-HSD). In a fed-batch fermentation at pilot scale (70 L) with a genetically improved production strain and under optimized reaction conditions, an average 20α-DHD production rate of 190 μM day−1 was determined for a total biotransformation time of 136 h. Combined with an effective and reliable downstream processing, a continuous production rate of 12.3 ± 1.4 g 20α-DHD per week and fermenter was achieved. We thus established an AKR-dependent whole-cell biotransformation process that can also be used for the production of other AKR1C1 substrates (as exemplarily shown by the production of 20α-dihydroprogesterone in gram scale) and is in principle suited for the production of further human AKR metabolites at industrial scale.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jin, Y., & Penning, T. M. (2007). Annual Review of Pharmacology and Toxicology, 47, 263–292.
Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., et al. (2000). The Biochemical Journal, 351, 67–77.
Penning, T. M. (1997). Endocrine Reviews, 18, 281–305.
Takegawa, K., Tohda, H., Sasaki, M., Idiris, A., Ohashi, T., Mukaiyama, H., et al. (2009). Biotechnology and Applied Biochemistry, 53, 227–235.
Zollner, A., Buchheit, D., Meyer, M. R., Maurer, H. H., Peters, F. T., & Bureik, M. (2010). Bioanalysis, 2, 1277–1290.
Naumann, J. M., Messinger, J., & Bureik, M. (2010). Journal of Biotechnology, 150, 161–170.
Chetrite, G. S., Thole, H. H., Philippe, J. C., & Pasqualini, J. R. (2004). Anticancer Research, 24, 1433–1438.
D'Incan, E., Loupy, A., Restelli, A., Seyden-Penne, J., & Viout, P. (1982). Tetrahedron, 38, 1755.
Choudhary, M. I., Jalil, S., & Musharraf, S. G. (2008). Chemistry & Biodiversity, 5, 324–331.
Azizuddin, Saifullah, Khan, S., Choudhary, M. I., & Atta-ur-Rahman. (2008). Turkish Journal of Chemistry, 32, 141–146.
Sambrook, J., Fritsch, E. F., & Maniatis, T. (1989). Molecular cloning: a laboratory manual (2nd ed.). Cold Spring Harbor: Cold Spring Harbor LaboratoryPress.
Burke, J. D., & Gould, K. L. (1994). Molecular & General Genetics, 242, 169–176.
Maundrell, K. (1993). Gene, 123, 127–130.
Craven, R. A., Griffiths, D. J., Sheldrick, K. S., Randall, R. E., Hagan, I. M., & Carr, A. M. (1998). Gene, 221, 59–68.
Forsburg, S. L., & Rhind, N. (2006). Yeast, 23, 173–183.
Suga, M., & Hatakeyama, T. (2005). Yeast, 22, 799–804.
Jansen, M. L., Krook, D. J., De Graaf, K., van Dijken, J. P., Pronk, J. T., & de Winde, J. H. (2006). FEMS Yeast Research, 6, 888–901.
Robinson, C. H., & Hofer, P. (1966). Chemistry and Industry, 377–378.
Bureik, M., & Bernhardt, R. (2007). Steroid hydroxylation. In: R. D. Schmid & V. Urlacher (Eds), Modern biooxidation, Wiley-VCH 155–176.
Bernhardt, R. (2006). Journal of Biotechnology, 124, 128–145.
Girhard, M., Klaus, T., Khatri, Y., Bernhardt, R., & Urlacher, V. B. (2010). Applied Microbiology and Biotechnology, 87, 595–607.
Petric, S., Hakki, T., Bernhardt, R., Zigon, D., & Cresnar, B. (2010). Journal of Biotechnology, 150, 428–437.
Zehentgruber, D., Dragan, C. A., Bureik, M., & Lutz, S. (2010). Journal of Biotechnology, 146, 179–185.
Zehentgruber, D., Hannemann, F., Bleif, S., Bernhardt, R., & Lutz, S. (2010). Chembiochem, 11, 713–721.
Bureik, M., Hübel, K., Dragan, C.-A., Scher, J., Becker, H., Lenz, N., et al. (2004). Molecular and Cellular Endocrinology, 217, 249–254.
Bureik, M., Lisurek, M., & Bernhardt, R. (2002). Biological Chemistry, 383, 1537–1551.
Dragan, C. A., Blank, L. M., & Bureik, M. (2006). Yeast, 23, 779–794.
Dragan, C.-A., Hartmann, R. W., & Bureik, M. (2006). Journal of Enzyme Inhibition and Medicinal Chemistry, 21, 547–556.
Dragan, C.-A., Zearo, S., Hannemann, F., Bernhardt, R., & Bureik, M. (2005). FEMS Yeast Research, 5, 621–625.
Dragan, C. A., Buchheit, D., Bischoff, D., Ebner, T., & Bureik, M. (2010). Drug Metabolism and Disposition, 38, 509–515.
Dragan, C. A., Peters, F. T., Bour, P., Schwaninger, A. E., Schaan, S. M., Neunzig, I., et al. (2011). Applied Biochemistry and Biotechnology, 163, 965–980.
Peters, F. T., Dragan, C. A., Kauffels, A., Schwaninger, A. E., Zapp, J., Bureik, M., et al. (2009). Journal of Analytical Toxicology, 33, 190–197.
Peters, F. T., Dragan, C. A., Schwaninger, A. E., Sauer, C., Zapp, J., Bureik, M., et al. (2009). Forensic Science International, 184, 69–73.
Peters, F. T., Dragan, C. A., Wilde, D. R., Meyer, M. R., Zapp, J., Bureik, M., et al. (2007). Biochemical Pharmacology, 74, 511–520.
Leroy-Lechat, F., Wouessidjewe, D., Andreux, J.-P., Puisieux, F., & Duchêne, D. (1994). International Journal of Pharmaceutics, 101, 97–103.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Naumann, J.M., Zöllner, A., Drăgan, CA. et al. Biotechnological Production of 20-alpha-Dihydrodydrogesterone at Pilot Scale. Appl Biochem Biotechnol 165, 190–203 (2011). https://doi.org/10.1007/s12010-011-9243-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-011-9243-x